Sonidegib: First Global Approval

Drugs
Celeste B Burness

Abstract

Sonidegib (Odomzo™) is an orally bioavailable, small molecule, Smoothened (SMO) receptor antagonist that is being developed by Novartis for the treatment of cancer. SMO is a G protein-coupled receptor-like molecule that is essential for the actions of the Hedgehog family of secreted proteins, which play a critical role in the development and homeostasis of many organs and tissues. Oral sonidegib is approved in Switzerland for the treatment of adult patients with advanced basal cell carcinoma (BCC) and in the US and EU for the treatment of adult patients with locally advanced BCC that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy. Submissions to other global authorities are being contemplated or planned. Additionally, phase I/II investigation is being conducted in other malignancies, including multiple myeloma, medulloblastoma, myelofibrosis, ovarian cancer, prostate cancer, breast cancer, chronic myeloid leukaemia, myelodysplastic syndromes, oesophageal cancer and pancreatic cancer. This article summarizes the milestones in the development of sonidegib leading to the first approvals for advanced and locally advanced BCC.

References

Sep 25, 2008·Nature Reviews. Cancer·Ervin H Epstein
Mar 25, 2011·The Journal of Investigative Dermatology·Hans SkvaraMenno A De Rie
May 4, 2012·Molecular Cancer Therapeutics·Adam D StegCharles N Landen
May 3, 2013·Nature·Chong WangRaymond C Stevens
Feb 14, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jordi RodonAlain C Mita
May 13, 2014·Cancer Chemotherapy and Pharmacology·Markus ZollingerPiet Swart
Dec 5, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Yaping ShouMark W Kieran

❮ Previous
Next ❯

Citations

Jan 3, 2016·Cancer Epidemiology·Haixia LiLimin Feng
Mar 19, 2016·Molecular Cancer·Ann Hanna, Lalita A Shevde
Apr 5, 2016·Organic & Biomolecular Chemistry·Katarzyna N LeeMing-Yu Ngai
Sep 17, 2016·Expert Review of Anticancer Therapy·Nicholas J CollierJohn T Lear
Apr 20, 2017·Journal of Medicinal Chemistry·Andrew C FlickChristopher J O'Donnell
Jan 10, 2018·Medicinal Research Reviews·Minhang XinBinghe Wang
Nov 23, 2017·Molecular Nutrition & Food Research·Cheng BaoNanjoo Suh
Mar 27, 2019·Future Medicinal Chemistry·Christian Espinosa-BustosCristian O Salas
Mar 5, 2016·World Journal of Gastroenterology : WJG·Simone PolvaniAndrea Galli
Apr 18, 2017·Laboratory Investigation; a Journal of Technical Methods and Pathology·Jia DingJian Wu
Apr 17, 2020·Dermatology and Therapy·Alessia VillaniMassimiliano Scalvenzi
Oct 24, 2018·Cancer Cell International·Babak OtoukeshMaria Kaghazian
Nov 19, 2020·Cellular and Molecular Neurobiology·Saloni Rahi, Sidharth Mehan
Nov 17, 2020·Frontiers in Oncology·Gabriella BrancaccioGiuseppe Argenziano
Apr 24, 2021·Expert Opinion on Drug Safety·Alessia VillaniMassimiliano Scalvenzi
Apr 28, 2021·European Journal of Medicinal Chemistry·Xiaoxia LiangBo Jing
May 25, 2021·World Journal of Gastroenterology : WJG·Faran PolaniKian-Huat Lim
Sep 28, 2017·ACS Medicinal Chemistry Letters·Simone GräßleStefan Bräse

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Basal Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.

Related Papers

Drugs
Shelley Elkinson, Paul L McCormack
American Journal of Clinical Dermatology
Katherine A Lyseng-Williamson, Gillian M Keating
Drugs
Sohita Dhillon, Madeleine Clark
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progrès Dans Les Recherches Sur Le Cancer
F Meiss, R Zeiser
© 2021 Meta ULC. All rights reserved